- Avant Technologies (OTCQB: AVAI) is launching a new company to enhance diabetes treatment programs.
- The company leverages its Vision AI platform for early detection of diabetic retinopathy and other diseases.
- With a global diabetes prevalence of over 500 million, Avant seeks to expand from diagnostics to treatment through strategic partnerships.
Avant Technologies Inc. (OTCQB: AVAI) has announced plans to form a new company focused on advancing diabetes treatment solutions. This strategic move is a continuation of Avant's existing collaboration with Ainnova Tech, under the joint venture Ai-nova Acquisition Corp (AAC), which incorporates the use of the Vision AI platform.
The Vision AI technology is designed to identify early signs of diabetic retinopathy and other health conditions, using retinal scans. This AI-driven platform promises high accuracy and fast results, tackling diseases such as cardiovascular and chronic kidney diseases, prediabetes, type 2 diabetes, and fatty liver diseases.
With over 500 million people diagnosed with diabetes worldwide, Avant Technologies aims to expand its scope beyond diagnostics to potentially include treatment development, facilitated through joint ventures, partnerships, or acquisitions. The company intends to be ready with a structured entity to accommodate upcoming opportunities in diabetes treatment advancements.
In late 2024, Avant entered a crucial joint venture with Ainnova Tech, establishing Ai-nova Acquisition Corp (AAC) to commercialize cutting-edge technologies, including Vision AI and versatile retinal cameras. The Vision AI platform is a significant innovation in the detection of diabetic retinopathy, a condition affecting over 30% of diabetics and a leading cause of blindness among working-age individuals.
Chris Winter, CEO of Avant, emphasized that the company's ongoing work with Ainnova is a driving force behind these new initiatives, as AVAI positions itself to significantly impact global diabetes treatment solutions.
